头颈部鳞状细胞癌GTV-CTV-PTV总外扩边界减少6 mm的剂量学与临床优势:显著降低急性和晚期毒性
该研究比较了头颈部鳞状细胞癌根治性放(化)疗中GTV-CTV-PTV总外扩边界9 mm(155例)与15 mm(155例)的剂量学和临床影响。9 mm组总 irradiated 体积中位减少28.1%,唾液腺和缩咽肌剂量显著降低,急性3级毒性、3级黏膜炎、治疗结束时喂养管依赖及晚期≥2级口干和吞咽困难均显著降低,两组2年局部区域控制、无病生存和总生存无显著差异。
要点
- GTV-CTV-PTV总外扩从15 mm减至9 mm使PTV-total中位减少28.1%,同侧腮腺剂量中位降低9.6 Gy。
- 9 mm组急性3级总毒性47.7% vs 15 mm组66.5%(p=0.001),3级黏膜炎18.1% vs 35.5%(p<0.001)。
- 9 mm组晚期≥2级口干31.7% vs 58.6%(p<0.001),≥2级吞咽困难15.4% vs 26.7%(p=0.04)。
核心结论
- 在头颈部鳞状细胞癌中,将GTV-CTV-PTV总外扩边界从15 mm减至9 mm显著降低了照射体积以及唾液腺和缩咽肌剂量,并显著降低了放疗相关毒性。
- 两组局部区域控制率相当。
研究设计与样本
- 研究比较了2017年2月至2019年3月间接受GTV-CTV-PTV总外扩9 mm的155例连续患者与2015年4月前接受总外扩15 mm的155例连续患者的急性和晚期毒性及结局。
- 所有患者均接受VMAT治疗,并采用CBCT进行每日图像引导。
主要发现
- GTV-CTV-PTV减少6 mm使PTV-total中位显著减少28.1%,并显著降低所有唾液腺剂量(同侧腮腺降低最多,中位-9.6 Gy)和缩咽肌剂量(-6.1 Gy)。
- 急性3级总毒性发生率9 mm组为47.7%,15 mm组为66.5%(p=0.001);3级黏膜炎9 mm组为18.1%,15 mm组为35.5%(p<0.001);治疗结束时喂养管依赖9 mm组为24.5%,15 mm组为40%(p=0.005)。
- 晚期≥2级口干发生率9 mm组为31.7%,15 mm组为58.6%(p<0.001);晚期≥2级吞咽困难9 mm组为15.4%,15 mm组为26.7%(p=0.04)。
- 2年局部区域控制率9 mm组为78.8%,15 mm组为75.8%;2年无病生存率9 mm组为70.9%,15 mm组为64.4%;2年总生存率9 mm组为83.8%,15 mm组为67.6%(p>0.05,所有比较)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aim to identify the dosimetric and clinical impact of reducing the total GTV-CTV-PTV margins in head-and-neck squamous cell carcinoma (HNSCC) treated with definitive (chemo)radiation. MATERIALS AND METHODS: The acute and late toxicity and outcomes of 155 consecutive patients treated between February 2017 and March 2019 with GTV-CTV-PTV margins of 9 mm were compared to those of 155 consecutive patients treated with total margin of 15 mm margin, before April 2015. All patients were treated with VMAT with daily-image guidance using CBCT. RESULTS: Reducing the GTV-CTV-PTV by 6 mm resulted in significant reduction of total irradiated volume (PTV-total) by a median of 28.1% and significant reduction of doses to all salivary glands (largest reduction ipsilateral parotid gland; median -9.6 Gy) and constrictor muscle (-6.1 Gy) with subsequent reduction of the incidence of overall acute grade 3 toxicity (47.7% for 9 mm and 66.5% for 15 mm groups, p = 0.001), grade 3 mucositis (18.1% vs. 35.5%, p < 0.001) and feeding tube-dependency at the end of treatment (24.5% vs. 40%, p = 0.005). The incidence of late grade ≥ 2 xerostomia and dysphagia were also significantly lower in the 9 mm group (31.7% vs. 58.6% p < 0.001, and 15.4% vs. 26.7%, p = 0.04). The 2-year rates of loco-regional control, disease-free and overall survival were 78.8% vs.75.8%, 70.9% vs. 64.4%, and 83.8% vs. 67.6%, (p > 0.05, all). CONCLUSION: Reduction of the total GTV-CTV-PTV margins from 15 to 9 mm in HNSCC significantly reduced the irradiated volumes and the dose to salivary glands and constrictor muscle with significant reduction of radiation-related toxicity. The loco-regional control rates of both groups were comparable.
引用
- Al-Mamgani A, Kessels R, Janssen T, et al. The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6 mm in head and neck squamous cell carcinoma: Significant acute and late toxicity reduction. Radiother Oncol. 2022. PMID: 35065998. doi:10.1016/j.radonc.2022.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。